Comparing various clinical and pathological features of samples, the level of DIRAS3 gene expression was significantly higher in malignant thyroid changes (FTC and PTC) than in benign lesions (NG and FA) (Figure 3b). This evidence concerns the gene DIRAS3 and thyroid cancer, nonmedullary, 2.